Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Ann Hematol. 2018 Mar 20;97(7):1183–1191. doi: 10.1007/s00277-018-3289-6

Table 2b.

Association between bone marrow fibrosis grade and patient characteristics

Variable  n (%)  p value
 Grade 0, 1  Grade 2
Sex
 Female  22 (88)  3 (12)  0.37
 Male  44 (77)  13 (23)
Race
 Non-white  3 (83)  1 (50)  0.61
 White  36 (80)  9 (20)
Hepatomegaly
 Yes  2 (50)  2 (50)
 No  64 (82)  14 (18)  0.17
Splenomegaly
 Yes  11 (73)  4 (27)
 No  54 (82)  12 (18)  0.48
Transfusion dependency
 Yes  22 (69)  10 (31)
 No  40 (87)  6 (13)  0.09
Treatment
 HMA  15 (79)  4 (21)  0.86
 HMA + combination  10 (77)  3 (23)
 TKI  1 (100)  0 (0)
 Chemotherapy  11 (92)  1 (8)
 Supportive therapy  29 (78)  8 (22)
IPSS cytogenetic risk group  0.51
 Poor  5 (71)  2 (29)
 Intermediate  11 (73)  4(27)
 Good or very good  50 (83)  10 (17)

Abbreviations: HMA=Hypomethylating agents, TKI=Tyrosine kinase inhibitors